1. Efficacy and safety of oxymetazoline cream 1
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial 
Zoe Diana Draelos, MD, Michael H. Gold, MD, Robert A. Weiss, MD, Leslie Baumann, MD, Steven K. Grekin, DO, Deanne Mraz Robinson, MD, Steven E. Kempers, MD, Nancy Alvandi, PhD, Emily Weng, ScD, MBA, David R. Berk, MD, Gurpreet Ahluwalia, PhD 
Journal of the American Academy of Dermatology 
Volume 78, Issue 6, Pages (June 2018)
DOI: /j.jaad
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Efficacy. Percentage of patients experiencing a composite 2-grade or greater improvement from baseline (before the dose on day 1) in Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA) (composite success). Analysis was based on observed cases at each time point in the modified intent-to-treat population.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Oxymetazoline efficacy over 6 hours after the dose in a female (A) and a male (B) patient with moderate-to-severe persistent erythema associated with rosacea. On the basis of a 2-grade or greater improvement from baseline (predose on day 1) on both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA), the female oxymetazoline-treated patient was considered a responder at hour 3 at week 26 and hour 6 at week 52 (A), and the male patient was a responder at hour 6 at week 26 and week 52 (B). One star indicates a 2-grade or greater improvement from baseline in CEA or SSA; 2 stars indicate a 2-grade or greater improvement from baseline in both CEA and SSA.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions